Physician profile
David W Moon
NPI 1417053133
$12,464.49
in general payments reported to CMS, 2019-2025
52 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $1,352 · 2021: $2,393 · 2022: $2,534 · 2023: $1,531 · 2024: $1,594 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,786.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,179.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,647.22 | 2019-2025 | |
| Novo Nordisk INC | $1,276.85 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $721.94 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.65 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $615.25 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $519.49 | 2022-2025 | |
| Astellas Pharma US INC | $421.98 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $403.93 | 2019-2022 | |
| Forte Bio-Pharma LLC | $383.88 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $252.78 | 2019-2025 | |
| Pfizer INC. | $222.81 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $217.11 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.51 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.